Greer Laboratories, Inc.

Greer Laboratories, Inc., doing business as Stallergenes Greer, manufactures allergen extract biological products, diagnostic testing antigens, diluents, and related medical supplies for the Defense Health Agency, the Department of the Army Medical Command, the Department of Veterans Affairs, and the National Institutes of Health as a prime contractor competing in open federal procurements with no set-aside designations. The company is a foreign-owned for-profit manufacturer headquartered in Lenoir, North Carolina, with a federal contracting footprint dating to 2002 and primary NAICS classification as Pharmaceutical Preparation Manufacturing (325412).

Greer's customer concentration is heavily skewed to military healthcare. The Department of the Army Medical Command and the Defense Health Agency together account for 100% of combined potential value across the portfolio — the Army commanding $31.5 million across 18 awards and the Defense Health Agency commanding $30.4 million across 21 awards. While the Navy, VA, and NIH appear in the broader award count (18% coverage), their combined potential value is negligible (less than $400 thousand). Greer's entire federal footprint centers on supplying the U.S. Army Centralized Allergen Extract Laboratory at Fort Meade, Maryland, which processes approximately 100,000 vials of allergy vaccines and diagnostics annually for over 500 military and VA medical facilities serving more than 30,000 patients. Performance occurs primarily at Fort Meade, Silver Spring, Maryland, and Lenoir, North Carolina.

Greer holds four active single-award indefinite delivery contracts with the Defense Health Agency and the Army Medical Command. The primary vehicle is a $7.68 million IDC awarded March 1, 2023, running through February 29, 2028, with six task orders issued to date totaling $1.3 million in combined potential value. A second $12 million IDC was awarded September 22, 2025, effective through September 21, 2030, with four task orders issued totaling approximately $1.2 million. Two intermediate-value IDCs — one for $2.53 million (June 4, 2025, completion December 3, 2025) and one for $2.23 million (September 27, 2024, completion March 27, 2025) — have generated additional task orders. Representative recent delivery orders include a $455,291 order placed September 30, 2026, a $1.09 million order placed June 4, 2025, and a $685,882 order placed June 6, 2025, all for allergen extract supplies to Fort Meade.

Activity has been episodic — seven awards in 2023, five in 2024, seven in 2025, and three in 2026 to date — with an average of approximately five awards annually over the past five years. Combined potential value across all 267 prime awards stands at $62.4 million, with $17.3 million obligated to date (28% execution rate). Greer competes without set-aside protection and does not subcontract; 100% of its federal footprint comprises direct prime awards. The procurements are categorized primarily under PSC Drugs and Biologicals (137 awards) and Medical and Surgical Instruments, Equipment, and Supplies (62 awards), with supplemental national laboratories work (9 awards). Greer's business model is specialized, repeating delivery against sole-source or FAR 6.302-1 authority indefinite delivery contracts requiring FDA-approved biologics and USP 797 compliance — a regulatory posture and specialized manufacturing capability that limits competition and anchors customer lock-in to the Army and Defense Health Agency.